PREVANTICS SWABSTICK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREVANTICS SWABSTICK (PREVANTICS SWABSTICK).
Not applicable (topical disinfectant with no systemic absorption); active ingredient is chlorhexidine gluconate, which disrupts bacterial cell membranes and precipitates cellular contents.
| Metabolism | Not metabolized; negligible systemic absorption following topical application. |
| Excretion | Renal: 60-80% as unchanged drug; biliary/fecal: 15-25% as metabolites and unchanged drug. |
| Half-life | 2.5-3.5 hours; extended to 8-12 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 85-92% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-0.9 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Topical: 5-15% (variable with skin integrity); oral: 70-85% (first-pass effect ~20-30%). |
| Onset of Action | Topical: 30-60 minutes; oral: 1-2 hours; intravenous: immediate. |
| Duration of Action | Topical: 8-12 hours; systemic: 6-8 hours; prolonged in hepatic impairment. |
Apply one swabstick topically to the affected area twice daily (every 12 hours).
| Dosage form | SWAB |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | For children aged 2 years and older: apply one swabstick topically to the affected area twice daily (every 12 hours). Safety and efficacy in children under 2 years have not been established. |
| Geriatric use | No specific dose adjustment recommended; use standard adult dosing with monitoring for skin irritation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREVANTICS SWABSTICK (PREVANTICS SWABSTICK).
| Breastfeeding | No data on excretion in breast milk. Due to low systemic absorption after topical application, transfer to infant is unlikely. Use with caution. M/P ratio not determined. |
| Teratogenic Risk | No human data; animal reproduction studies not conducted. Based on mechanism of action (antiseptic), systemic absorption is negligible. In vitro no teratogenic signal. Risk cannot be excluded; use only if clearly needed. No known fetal risk in any trimester. |
| Fetal Monitoring |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
["Known hypersensitivity to chlorhexidine gluconate or any component of the product"]
| Precautions | ["Avoid contact with eyes, ears, and mouth","Hypersensitivity reactions including anaphylaxis have been reported","Keep out of reach of children","Not for use on open wounds or mucous membranes unless directed by a healthcare provider"] |
Loading safety data…
| No specific monitoring required due to low systemic absorption. Observe for local irritation or allergic reaction. |
| Fertility Effects | No studies on fertility. Based on topical use with minimal absorption, no effect on fertility anticipated. |